|
|
|
1
|
Lecour S, Merwe EV, Opie LH, Sack MN.
Ceramide Attenuates Hypoxic Cell Death via Reactive Oxygen Species Signaling.
J Cardiovasc Pharmacol 47(1): 158-163, 2006.
[Text Abstract on PubMed]
|
|
|
2
|
Makaula S, Lochner A, Genade S, Sack MN, Awan MM, Opie LH.
H-89, a non-specific inhibitor of protein kinase A, promotes post-ischemic cardiac contractile recovery and reduces infarct size.
J Cardiovasc Pharmacol 45(4): 341-7, 2005.
[Text Abstract on PubMed]
|
|
|
3
|
McCarthy J, McLeod CJ, Minners J, Essop MF, Ping P, Sack MN.
PKCepsilon activation augments cardiac mitochondrial respiratory post-anoxic reserve--a putative mechanism in PKCepsilon cardioprotection.
J Mol Cell Cardiol 38(4): 697-700, 2005.
[Text Abstract on PubMed]
|
|
|
4
|
McLeod CJ, Aziz A, Hoyt RF, McCoy JP, Sack MN.
Uncoupling proteins 2 and 3 function in concert to augment tolerance to cardiac ischemia.
J Biol Chem 280(39): 33470-6, 2005.
[Text Abstract on PubMed]
|
|
|
5
|
McLeod CJ, Pagel I, Sack MN.
The mitochondrial biogenesis regulatory program in cardiac adaptation to ischemia--a putative target for therapeutic intervention.
Trends Cardiovasc Med 15(3): 118-23, 2005.
[Text Abstract on PubMed]
|
|
|
6
|
Essop MF, Razeghi P, McLeod C, Young ME, Taegtmeyer H, Sack MN.
Hypoxia-induced decrease of UCP3 gene expression in rat heart parallels metabolic gene switching but fails to affect mitochondrial respiratory coupling.
Biochem Biophys Res Commun 314(2): 561-4, 2004.
[Text Abstract on PubMed]
|
|
|
7
|
Jonassen AK, Mjøs OD, Sack MN.
p70s6 kinase is a functional target of insulin activated Akt cell-survival signaling.
Biochem Biophys Res Commun 315(1): 160-5, 2004.
[Text Abstract on PubMed]
|
|
|
8
|
McLeod CJ, Jeyabalan AP, Minners JO, Clevenger R, Hoyt RF, Sack MN.
Delayed ischemic preconditioning activates nuclear-encoded electron-transfer-chain gene expression in parallel with enhanced postanoxic mitochondrial respiratory recovery.
Circulation 110(5): 534-9, 2004.
[Text Abstract on PubMed]
|
|
|
9
|
Smith RM, Suleman N, Lacerda L, Opie LH, Akira S, Chien KR, Sack MN.
Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning.
Cardiovasc Res 63(4): 611-6, 2004.
[Text Abstract on PubMed]
|
|
|
10
|
Lecour S, Sack MN, Opie LH.
[Sphingolipid signaling: a potential pathway for TNF-alpha induced preconditioning]
Ann Cardiol Angeiol (Paris) 52(6): 363-9, 2003.
[Text Abstract on PubMed]
|
|
|
11
|
Minners J, McLeod CJ, Sack MN.
Mitochondrial plasticity in classical ischemic preconditioning-moving beyond the mitochondrial KATP channel.
Cardiovasc Res 59(1): 1-6, 2003.
[Text Abstract on PubMed]
|
|
|
12
|
Ngumbela KC, Sack MN, Essop MF.
Counter-regulatory effects of incremental hypoxia on the transcription of a cardiac fatty acid oxidation enzyme-encoding gene.
Mol Cell Biochem 250(1-2): 151-8, 2003.
[Text Abstract on PubMed]
|
|
|
13
|
Sack MN, Yellon DM.
Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation.
J Am Coll Cardiol 41(8): 1404-7, 2003.
[Text Abstract on PubMed]
|
|
|
14
|
Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN.
Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection.
J Mol Cell Cardiol 34(5): 509-18, 2002.
[Text Abstract on PubMed]
|
|
|
15
|
Opie LH, Sack MN.
Metabolic plasticity and the promotion of cardiac protection in ischemia and ischemic preconditioning.
J Mol Cell Cardiol 34(9): 1077-89, 2002.
[Text Abstract on PubMed]
|
|
|
16
|
Smith RM, Lecour S, Sack MN.
Innate immunity and cardiac preconditioning: a putative intrinsic cardioprotective program.
Cardiovasc Res 55(3): 474-82, 2002.
[Text Abstract on PubMed]
|
|
|
17
|
Jonassen AK, Sack MN, Mjøs OD, Yellon DM.
Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling.
Circ Res 89(12): 1191-8, 2001.
[Text Abstract on PubMed]
|
|
|
18
|
Minners J, Lacerda L, McCarthy J, Meiring JJ, Yellon DM, Sack MN.
Ischemic and pharmacological preconditioning in Girardi cells and C2C12 myotubes induce mitochondrial uncoupling.
Circ Res 89(9): 787-92, 2001.
[Text Abstract on PubMed]
|
|
|
19
|
Opie LH, Sack MN.
Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes.
Circ Res 88(7): 654-8, 2001.
[Text Abstract on PubMed]
|
|
|
20
|
Smith RM, McCarthy J, Sack MN.
TNF alpha is required for hypoxia-mediated right ventricular hypertrophy.
Mol Cell Biochem 219(1-2): 139-43, 2001.
[Text Abstract on PubMed]
|
|
|
21
|
Awan MM, Makaula S, Forresti S, Sack MN, Opie LH.
Mechanisms whereby glucose deprivation triggers metabolic preconditioning in the isolated rat heart.
Mol Cell Biochem 211(1-2): 111-21, 2000.
[Text Abstract on PubMed]
|
|
|
22
|
Bell SP, Sack MN, Patel A, Opie LH, Yellon DM.
Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle.
J Am Coll Cardiol 36(7): 2296-302, 2000.
[Text Abstract on PubMed]
|
|
|
23
|
Jonassen AK, Brar BK, Mjøs OD, Sack MN, Latchman DS, Yellon DM.
Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism.
J Mol Cell Cardiol 32(5): 757-64, 2000.
[Text Abstract on PubMed]
|
|
|
24
|
Minners J, van den Bos EJ, Yellon DM, Schwalb H, Opie LH, Sack MN.
Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection.
Cardiovasc Res 47(1): 68-73, 2000.
[Text Abstract on PubMed]
|
|
|
25
|
Sack MN, Harrington LS, Jonassen AK, Mjøs OD, Yellon DM.
Coordinate regulation of metabolic enzyme encoding genes during cardiac development and following carvedilol therapy in spontaneously hypertensive rats.
Cardiovasc Drugs Ther 14(1): 31-9, 2000.
[Text Abstract on PubMed]
|
|
|
26
|
Sack MN, Smith RM, Opie LH.
Tumor necrosis factor in myocardial hypertrophy and ischaemia--an anti-apoptotic perspective.
Cardiovasc Res 45(3): 688-95, 2000.
[Text Abstract on PubMed]
|
|
|
27
|
Sack MN, Kelly DP.
The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review).
Int J Mol Med 1(1): 17-24, 1998.
[Text Abstract on PubMed]
|
|
|
28
|
Sack MN, Disch DL, Rockman HA, Kelly DP.
A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program.
Proc Natl Acad Sci U S A 94(12): 6438-43, 1997.
[Text Abstract on PubMed]
|
|
|
29
|
Bui MN, Sack MN, Moutsatsos G, Lu DY, Katz P, McCown R, Breall JA, Rackley CE.
Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis.
Am Heart J 131(4): 663-7, 1996.
[Text Abstract on PubMed]
|
|
|
30
|
Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP.
Fatty acid oxidation enzyme gene expression is downregulated in the failing heart.
Circulation 94(11): 2837-42, 1996.
[Text Abstract on PubMed]
|
|
|
31
|
Gilligan DM, Sack MN, Guetta V, Casino PR, Quyyumi AA, Rader DJ, Panza JA, Cannon RO.
Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia.
J Am Coll Cardiol 24(7): 1611-7, 1994.
[Text Abstract on PubMed]
|
|
|
32
|
Sack MN, Hoeg JM.
Restriction isotyping of apoprotein E.
Ann Intern Med 121(10): 816, 1994.
[Text Abstract on PubMed]
|
|
|
33
|
Sack MN, Rader DJ, Cannon RO.
Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women.
Lancet 343(8892): 269-70, 1994.
[Text Abstract on PubMed]
|
|
|